Table 3.
Epigenetic inhibitors tested in the clinic in combination with immunotherapies (active trials).
| Epi- therapy | Immunotherapy |
Indication | Clinical trial Number | |
|---|---|---|---|---|
| Vaccine | Checkpoint therapy | |||
| Demethylation agents (DNMTi) Azacytidine, Decitabine |
Allogeneic colon cancer cell vaccine (GVAX) and cyclophosphamide | Metastatic colon cancer | NCT01966289 | |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401 | MDS/AML | NCT03358719 | ||
| Pembrolizumab | Metastatic melanoma, NSCLC | NCT02816021, NCT02546986 | ||
| Nivolumab and/or Ipilimumab | MDS | NCT02530463 | ||
| HDACi ACY-241, Entinostat, ZEN-3694 |
Nivolumab and Ipilimumab | Metastatic unresectable HER2-negative breast cancer, NSCLC, Solids |
NCT02453620 NCT02635061 NCT04840589 |
|
| Pembrolizumab | Metastatic CRPC | NCT04471974 | ||
| EZH2i CPI-1205, DS-3201 |
Pembrolizumab | Advanced urothelial cancer, NSCLC, Head & Neck |
NCT03854474 NCT05879484 |
|
| Ipilimumab | Metastatis Prostate, Urothelial and Renal cell cancers | NCT04388852 | ||
| Atezolizumab and Bevacizumab | Hepatocellular Carcinoma | NCT06294548 | ||
| Rituximab | Follicular Lymphoma | NCT05683171 | ||
| SHR1701 | R/R cHL, Advanced solids R/R BC NHL |
NCT05896046 NCT04407741 |
||
| BETi INCB057643, BMS986158 |
Pembrolizumab + Epacadostat (IDO1 inhibitor) | Advanced solid cancers | NCT02959437 | |
| Ruxolitinib or Fedratinib | Myelofibrosis | NCT04817007 | ||
| LSD1i ORY-1001,IMG-7289 |
Atezolizumab | SCLC |
NCT06287775 NCT05191797 |
|